These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34751270)

  • 1. Camel nanobodies broadly neutralize SARS-CoV-2 variants.
    Hong J; Kwon HJ; Cachau R; Chen CZ; Butay KJ; Duan Z; Li D; Ren H; Liang T; Zhu J; Dandey VP; Martin N; Esposito D; Ortega-Rodriguez U; Xu M; Borgnia MJ; Xie H; Ho M
    bioRxiv; 2021 Oct; ():. PubMed ID: 34751270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants.
    Hong J; Kwon HJ; Cachau R; Chen CZ; Butay KJ; Duan Z; Li D; Ren H; Liang T; Zhu J; Dandey VP; Martin NP; Esposito D; Ortega-Rodriguez U; Xu M; Borgnia MJ; Xie H; Ho M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2201433119. PubMed ID: 35476528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants.
    Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Cetrulo Lorenzi JC; Park S; Wang Z; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
    bioRxiv; 2021 Mar; ():. PubMed ID: 33688659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library.
    González-González E; Carballo-Uicab G; Salinas-Trujano J; Cortés-Paniagua MI; Vázquez-Leyva S; Vallejo-Castillo L; Mendoza-Salazar I; Gómez-Castellano K; Pérez-Tapia SM; Almagro JC
    Antibodies (Basel); 2022 Sep; 11(3):. PubMed ID: 36134953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.
    Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U
    EMBO Rep; 2022 Feb; 23(2):e53865. PubMed ID: 34927793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants.
    Zupancic JM; Schardt JS; Desai AA; Makowski EK; Smith MD; Pornnoppadol G; Garcia de Mattos Barbosa M; Cascalho M; Lanigan TM; Tessier PM
    Adv Ther (Weinh); 2021 Aug; 4(8):2100099. PubMed ID: 34514086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
    Qu Y; Zhang X; Wang M; Sun L; Jiang Y; Li C; Wu W; Chen Z; Yin Q; Jiang X; Liu Y; Li C; Li J; Ying T; Li D; Zhan F; Wang Y; Guan W; Wang S; Liang M
    Virol Sin; 2021 Oct; 36(5):934-947. PubMed ID: 34224110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.
    Xu S; Wang Y; Wang Y; Zhang C; Hong Q; Gu C; Xu R; Wang T; Yang Y; Zang J; Zhou Y; Li Z; Liu Q; Zhou B; Bai L; Zhu Y; Deng Q; Wang H; Lavillette D; Wong G; Xie Y; Cong Y; Huang Z
    Emerg Microbes Infect; 2022 Dec; 11(1):351-367. PubMed ID: 34964428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2.
    Pymm P; Redmond SJ; Dolezal O; Mordant F; Lopez E; Cooney JP; Davidson KC; Haycroft ER; Tan CW; Seneviratna R; Grimley SL; Purcell DFJ; Kent SJ; Wheatley AK; Wang LF; Leis A; Glukhova A; Pellegrini M; Chung AW; Subbarao K; Uldrich AP; Tham WH; Godfrey DI; Gherardin NA
    iScience; 2022 Nov; 25(11):105259. PubMed ID: 36213007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2.
    Cross FR; Fridy PC; Ketaren NE; Mast FD; Li S; Olivier JP; Pecani K; Chait BT; Aitchison JD; Rout MP
    J Biol Chem; 2023 Mar; 299(3):102954. PubMed ID: 36720309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope.
    VanBlargan L; Adams L; Liu Z; Chen RE; Gilchuk P; Raju S; Smith B; Zhao H; Case JB; Winkler ES; Whitener B; Droit L; Aziati I; Shi PY; Creanga A; Pegu A; Handley S; Wang D; Boon A; Crowe JE; Whelan SPJ; Fremont D; Diamond M
    bioRxiv; 2021 Apr; ():. PubMed ID: 33907753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
    Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
    J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; Rezende E Mello JDF; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley T; Hsu A; Dandey V; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    bioRxiv; 2022 Mar; ():. PubMed ID: 34729560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.